ReviewTissue engineering and regenerative medicine2026
Polydeoxyribonucleotide (PDRN) in Dentistry: Narrative Review for Mechanisms and Emerging Clinical Applications.
Review in Tissue engineering and regenerative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Regulatory T Cells in Peri-implant Diseases: Current Osteoimmunologic Perspectives and Translational Challenges.Tissue engineering and regenerative medicine · 2026Review
- The Role of Polydeoxyribonucleotide as a Biotherapy for Musculoskeletal Disorders.International journal of molecular sciences · 2026Review
- Hyaluronic Acid Fillers Versus Polynucleotides for Under-Eye Rejuvenation.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundPolydeoxyribonucleotide (PDRN) has emerged as a promising and cost-effective biological agent in regenerative medicine due to its anti-inflammatory, angiogenic, and tissue-regenerative properties.
methodsThis review outlines the mechanisms of action of PDRN, namely activation of the A
resultsIn dentistry, PDRN has been shown to enhance osteogenesis and vascularization when used with bone graft scaffolds, to exert anti-inflammatory and chondroprotective effects in temporomandibular joint disorders, and to modulate pain pathways in neuropathic conditions. It has also demonstrated adjunctive benefits in managing inflammatory oral diseases such as peri-implantitis and medication-related osteonecrosis of the jaw, where its dual regenerative and anti-inflammatory actions support both soft- and hard-tissue healing.
conclusionAlthough these findings highlight broad therapeutic potential, current evidence remains limited. Most reports derive from preclinical experiments or small-scale clinical studies, and well-designed randomized controlled trials are needed to validate efficacy of PDRN and define its optimal clinical indications in evidence-based dental protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.